What is William Blair’s Forecast for KZR Q1 Earnings?

Kezar Life Sciences, Inc. (NASDAQ:KZR) – Investment analysts at William Blair issued their Q1 2026 earnings per share estimates for Kezar Life Sciences in a research report issued on Tuesday, March 25th. William Blair analyst M. Phipps expects that the company will post earnings of ($2.95) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($4.39) per share. William Blair also issued estimates for Kezar Life Sciences’ Q2 2026 earnings at ($3.03) EPS, Q3 2026 earnings at ($3.10) EPS and Q4 2026 earnings at ($3.16) EPS.

Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($2.77) EPS for the quarter, missing the consensus estimate of ($2.71) by ($0.06).

KZR has been the topic of a number of other research reports. Wells Fargo & Company reduced their price objective on Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 19th. HC Wainwright restated a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, December 2nd.

Kezar Life Sciences Stock Down 4.1 %

Shares of NASDAQ:KZR opened at $4.92 on Friday. Kezar Life Sciences has a 52-week low of $4.90 and a 52-week high of $9.27. The company has a market capitalization of $35.95 million, a PE ratio of -0.37 and a beta of 0.49. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.65 and a current ratio of 7.65. The company has a fifty day moving average of $6.00 and a 200-day moving average of $6.69.

Institutional Trading of Kezar Life Sciences

Several institutional investors have recently modified their holdings of KZR. Ikarian Capital LLC raised its position in Kezar Life Sciences by 23.0% during the 3rd quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock worth $827,000 after purchasing an additional 200,000 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Kezar Life Sciences by 15.0% in the third quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock valued at $485,000 after buying an additional 81,678 shares during the period. Peapod Lane Capital LLC acquired a new stake in shares of Kezar Life Sciences in the fourth quarter valued at about $833,000. Shay Capital LLC bought a new position in shares of Kezar Life Sciences during the fourth quarter worth about $398,000. Finally, XTX Topco Ltd lifted its stake in shares of Kezar Life Sciences by 256.1% in the third quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock worth $40,000 after acquiring an additional 37,504 shares during the period. Institutional investors own 67.90% of the company’s stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.